Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin plus Lantus, Pioglitazone, or DPP4 inhibitor in T2DM and Fatty Liver
NCT02365233Phase 4Terminated
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- May 2013
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine, pioglitazone, sitagliptin, saxagliptin in type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), sponsored by The University of Texas Medical Branch at Galveston. Started May 2013; status: terminated.
02
Drugs
insulin glarginepioglitazonesitagliptinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02365233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365233.